Investor Relations Presentation...2021/01/21 · packaging, with conception -to-launch and turnkey...

Investor Relations Presentation

January 2021

Forward Looking Statements & Non-GAAP Financial Measures

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s beliefs and assumptions in light of information currently available to management. Accordingly, the Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company’s operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.

During the course of this presentation, certain non-GAAP financial information will be presented.

A reconciliation of those numbers to GAAP financial measures is available on the company’s website at www.aptar.com on the Investor’s page (click on Events & Presentations / Presentations).

Overview

SALES BY REGION

55%33%

ATTRACTIVE END MARKETS

SERVING BEST KNOWN GLOBAL & LOCAL BRANDS

DIVERSIFIED PORTFOLIO

RESEARCH AND IP-DRIVEN

1,250Patent Families

Approximately3%R & D

Of Annual Revenue

THE LEADER IN CONSUMER DISPENSING AND DRUG DELIVERY

75-year history of innovation

Providing brand differentiation and consumer / patient convenience

Consistent long-term focus, stability and financial results

$2.9 bil*

*2019 Annual Revenue

We transform ideas into products and services that transform lives.

Examples of Products Counting on Aptar Drug Delivery and Dispensing Solutions (many are critical during the pandemic)

Rescue Drugs and Therapies

Preventive Medicines and Diagnostics Hand Sanitizers

Disinfectants Infant Nutrition

Pantry Staples

Pharma Beauty + Home Food + Beverage

Leveraging Deep Industrial and Product Knowhow Globally Across Three Reporting Segments

6* - LTM = Last twelve months ending September 30, 2020; the EBITDA %’s of LTM values are calculated on total Segment Adjusted EBITDA and exclude Corporate Expenses

Common Technologies and Solutions… …Serving Three Market-facing Reporting Segments

Core Manufacturing Technologies1

Best-in-Class Products and Services2

Aimed at Global Megatrends3

Precision Injection Molding

High-Speed Assembly

Metal Processing + Decorating

Material Science/Active Packaging

Dispensing and Delivery

Sealing

Active Packaging

Sustainability

Health + Wellness

Connectivity

Urbanization

Changing Demographics

e-Commerce/Individualization

% of Total LTM* Sales % of Total LTM* EBITDA

35% EBITDA Margin

10% EBITDA Margin

17% EBITDA Margin

$1.2 bil

$1.3 bil

$0.4 bil

$418 mil

$131 mil

$65 mil

YTD 2020 Recap

• Impact of COVID-19 tracking with our expectations from earlier this year: Q2 was low-point, markets generally performing as anticipated, gradual recovery in process

• Best of breed Pharma business continued to grow device and component sales in each market over very strong prior year

• Strong growth in Q2 and Q3 sales to the Personal Care market partially offsetting decreased sales to the Beauty Market

• Good growth in sales to the Food market offsetting decreased sales to the Beverage market

• Recent acquisitions performing well including FusionPKG and Nobel International

• Generating strong level of cash flow above prior year levels

Aptar Pharma Advertisement-8%-6%-4%-2%0%2%4%6%8%

Q1 Q2 Q3

Sales Growth by Quarter 2020

Reported Core

Anticipated Pandemic Impact 2020

Pharma Segment

Aptar Pharma Today

SALES BY REGION (2020)

65%29%

SALES BY MARKET (2020)

12% Prescription

Consumer HealthCareInjectables

Active Packaging

CUSTOMERS (Approx. 3,000)

INNOVATIVE SOLUTIONS

PATENTS

PATIENT / CONSUMER EXPERIENCE

8 BillionOver

Solutions per Year

750Patent Families

Managing close to

Successful long-term track record with over 150 approved NDAs, ANDAs and INDs in

past five years

Leader in Delivery Systems for Traditional Therapies

Nasal Delivery Solutions Eye Care Delivery Solutions Pulmonary Delivery SolutionsGlobal leader in nasal devices for Allergic Rhinitis, Aptar Pharma delivers across a

wide spectrum of nasal needs, from respiratory and allergy treatments to

vaccines and crisis medications.

Global leader in pressurized metered dose inhaler (pMDI) valves. We address the

Asthma and COPD therapy markets with a broad range of devices including pMDI

valves, Dry Powder Inhalers (DPIs), and electronic and connected devices.

Our Ophthalmic Squeeze Dispenser is the leading device for preservative-free multidose prescription medications and OTC eye care products with over 250

references on the market.

Growth from Drugs Repurposed for New Delivery Formats

Bidose Nasal Spray Device Nasal Unidose DevicesProtective Active Packaging Container and Unidose Powder System Device

Recent examples:

Anti-depressant Therapy Hypoglycemic Crisis Treatment Epilepsy Seizure Treatments

Growth in the Injectables Market

Proven injectables partner• 450+ customers in 70+ countries

worldwide

• Working with all of the top 10 Pharma players in injectables

• 70 of the 100 top molecules, mostly life saving treatments

COVID-19 Opportunities

• > 100 injectable vaccines / antiviral treatments being explored

• Increase in emergency / antibiotics treatments

• QuickStart™ turnkey solution for clinical development

Added-value solutions to meet most stringent market requirements around the development of complex & highly sensitive drug formulations

• PremiumCoat™

• Premium Fill®

• Premium Vision™

Global manufacturing network expansion to meet fast

growing demand

Expanding Our Pharma Services Platform

Foundation for Future Growth: Support through every step of the drug development journey

Guiding you through every step of drug product development

Device & formulation

developmentClinical trials Regulatory

filingsMarket launch &

post-launch

A global leader in patient onboarding and adherence programs.

A leading provider of orally inhaled & nasal drug product design & development services.

A full-service cGMPlab specializing in analytical testing of drug delivery systems.

A full-service cGMP lab providing industry-leading particulate detection & predictive analytical services.

A global provider of innovative drug delivery systems and service solutions.

Aptar Pharma Services

Q3 Segment Recap and New Product LaunchesAptar Pharma• Core sales growth of our devices and primary

components in each end market

• Some tailwinds from COVID-19-related demand for elastomer components

• Flu vaccine demand

• High level of hospitalizations resulting in increase in number of injected medicines

• Some early-stage stopper orders

• Launched AdhereIT™, a connected onboarding solution for patients who use autoinjectors

• Bag-on-valve system and actuator featured on Vicks Sinex™ Saline Ultra Fine Nasal Mist

• Proven unidose nasal system chosen for a new naloxone spray called Ventizolvelaunched in Europe

AdhereIT™

Aptar Pharma Advertisement

Growth in Active Packaging Solutions

Glucose Test Strips

EUA Filed April 2020: Introducing ActivShield™ Solution for Virus Mitigation on N95 Masks

ActivShield™ strips are 10mm x 10mm x 0.3mm thick

ActivShield™ is a safe and convenient way to deliver antimicrobial & antiviral treatment of N95 masks on site.

ActivShield™ production can quickly ramp to 10 million per week

Aptar Pharma

Q3 2020 Results

(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,

depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.

Metric 3 Year Average

Q32020

Long-term Target

Core sales growth1 10% 11% 6-10%

Adj. EBITDA2 margin 35% 36% 32-36%

$269$316

Q3 2019 Q3 2020

Reported

Core 11%

Acquisitions 2%

Currency Effects

36% 36%

Q3 2019 Q3 2020

Adjusted EBITDA(2) Margin %

Aptar Pharma

YTD 2020 Results

depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.

YTD2020

Long-term Target

Core sales growth1 10% 8% 6-10%

Adj. EBITDA2 margin 35% 36% 32-36%

$824$914

$1,000

YTD 2019 YTD 2020

Reported

Core 8%

Acquisitions 3%

Currency Effects

36% 36%

YTD 2019 YTD 2020

Adjusted EBITDA(2) Margin%

Beauty + Home Segment

52%30%

Beauty

Personal Care

Home Care

CUSTOMERS (6,000+)

PATENTS

CONSUMER EXPERIENCE

16 BillionOver

Solutions per year

400Patent Families

Aptar Beauty + Home Today

A significant amount of Europe sales end up in Asia in luxury and travel

Beauty Home Care StaplesPersonal Care EssentialsGlobal leader in the beauty packaging

industry, known for combining functional dispensing with premium aesthetics. We provide solutions for the luxury facial skin care, cosmetic and perfumery markets, as

well as turnkey solutions ideal for indie brands and the fast beauty market.

Providing a wide variety of solutions for liquid soaps, hand sanitizers, sun

protection, hair care products and body lotions. Sustainability is a focus and in

addition to using PCR, Aptar’s pumps are currently being used on refillable personal

care products for TerraCycle’s Loop platform.

Full range of dispensing systems for staples such as surface cleaners and disinfectants, air fresheners, and pet

Broad Portfolio of Brand-differentiating Solutions

Strategic Steps to Strengthen Our Beauty Business

BTY• Recently acquired a 49% equity

interest in BTY• Leading Chinese manufacturer of high

quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry

Ongoing Footprint Consolidation• We are closing our Stratford and Torrington

(CT) sites in the US, and our Ballinasloe site in Ireland; will absorb and rationalize production capacities into existing otherfacilities

• Better positions us to serve our customers and focus on long-term, profitable growth

• Continuation of other steps we have made to streamline our Beauty + Home footprint (facility consolidations in India, Argentina and Southeast Asia, and sale of molding facility in the US)

FusionPKG• Recently acquired FusionPKG, leader in high

quality, prestige airless and color cosmetics packaging, with conception-to-launch and turnkey solutions for the North American beauty market

• Proven creativity, engineering, formulation and fast go-to-market capabilities – ‘fast-beauty’

• Existing relationships with both global cosmetic and skin care customers and with many indie brands

• Potential to scale this beyond North America to other regions

Q3 Segment Recap and New Product Launches

Aptar Beauty + Home• Strong demand in the personal care market for

dispensing pumps and closures for hand sanitizers and liquid soaps

• Increased sales to the home care market primarily related to cleaners and disinfectants

• Beauty market continues to be negatively impacted by the effects of COVID-19

• Launched spray pumps and closures for Zest antibacterial sprays and soaps

• Lotion pumps are featured on new antibacterial hand soap for Vaseline® and Life Buoy brands and spray pump found on Colgate® mouth protect

• Spray pumps for new perfume and cologne launches including Tribeca by Bond No. 9®, Tom Ford by Estée Lauder™, Peony Rose by Avon ®

and many others

Aptar Beauty + Home

Q3 2020 Results

depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting

adjustments.

Q3 2020

Long-term Target

Core sales growth(1) 3% -5% 3-6%

Adj. EBITDA(2) margin 13% 10% 15-17%

$328 $337

Q3 2019 Q3 2020

Core -5%

Acquisitions 7%

Currency Effects

Reported

Q3 2019 Q3 2020

Aptar Beauty + Home

YTD 2020 Results

adjustments.

YTD 2020

Long-term Target

Adj. EBITDA(2) margin 13% 10% 15-17%

$1,038$962

$1,000

$1,200

YTD 2019 YTD 2020

Reported

-7%Core -9%

Acquisitions 4%

Currency Effects

YTD 2019 YTD 2020

Food + Beverage Segment

28%57%

26%Food

Beverage

CUSTOMERS (>200 clients with top 20 representing 65% of sales)

PATENTS

CONSUMER EXPERIENCE

Aptar Food + Beverage Today

7 BillionOver

Solutions per Year

150Patent Families

Food ProtectionAptar Food + Beverage is setting new standards to improve food safety. Our active packaging technology protects fresh cut produce and fresh seafood from harmful pathogens like bacteria,

fungi and viruses.

On-The-Go BeverageAptar serves the beverage market

by providing closures for sports drinks, drinkable dairy, juices and

bottled water. We reinvent and improve the drinking experience with tethered caps, child-friendly closures and e-commerce ready

solutions.

Fridge and Pantry Staples

Aptar Food + Beverage uses our innovative technologies to reinvent

everyday staples. Our solutions provide product differentiation for customers on the grocery store

shelf and improved functionality for the end user.

Consumer-focused, Value-driven Applications

Sustainable and Convenient Solutions

Tethered SolutionsOur tethered solutions improve the recyclability of bottle caps as they

stay connected to the bottle throughout its lifecycle.

Flexible Packaging

As a leader in the development of flexible package dispensing, we are helping

customers increase their market share with innovative, best-in-class pouch fitments (sealing and tamper evidence) and flow-

controlling dispensing solutions.

Q3 Segment Recap and New Product LaunchesAptar Food + Beverage• Strong core growth in the food market attributed to

the demand for pantry staples with consumers continuing to dine at home

• Lower sales to the beverage market due to the on-the-go beverage category being affected by the pandemic

• Effects of passing through lower resin prices to customers also affected the segment’s overall growth

• Helped bring to market the limited edition, in-store Big Mac® sauce for McDonalds in Brazil featuring our closure

• Added value to new product launches in the US with closures and SimpliSqueeze® valves including Old El PasoTM taco sauce and a new oral hygiene water enhancer for pets called Tally-Ho by Ocean Spray

Aptar Food + Beverage

Q3 2020 Results

adjustments.

Q3 2020

Long-term Target

Core sales growth(1) 5% 2% 6-10%

Adj. EBITDA(2) Margin 16% 19% 18-21%

$104 $106

Q3 2019 Q3 2020

Reported

Core 2%

Acquisitions0%

Currency Effects

18% 19%

Q3 2019 Q3 2020

Aptar Food + Beverage

YTD 2020 Results

adjustments.

YTD 2020

Long-term Target

Adj. EBITDA(2) Margin 16% 18% 18-21%

$327$304

YTD 2019 YTD 2020

Reported-7%

Core -5%

Acquisitions0%

Currency Effects

17% 18%

YTD 2019 YTD 2020

Appendix

Financial Results

Third Quarter 2020 Reported Results

Q3 Highlights• Very good quarter that speaks to

the resilience of our broad portfolio and, our diverse and attractive end markets

• Pharma segment reported impressive growth compared to a strong quarter a year ago

• Core sales growth in the food, personal care and home care markets

• Sales to the beauty and beverage markets continue to be impacted by COVID-19 pandemic

+2%Core Sales

Growth*

+2%Currency Effects

+4%Acquisitions

31%Q3 2019Reported

Effective Tax Rate

29%Q3 2020Reported

Effective Tax Rate

$701$759

Q3 2019 Q3 2020

Reported Q3 Sales(in millions $)

+8% $0.85 $0.95

Q3 2019 Q3 2020

Reported Q3 EPS+12%

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.

Adjustments: • 2019: Restructuring initiatives of $6.0 mil;

transaction costs related to acquisitions of $0.7 mil

• 2020: Restructuring initiatives of $3.4 mil; Transaction costs related to acquisitions of $0.2 mil

Third Quarter 2020 Adjusted EPS and Adjusted EBITDA

31%Q3 2019Effective Tax

Rate Adjusted Earnings*

28%Q3 2020Effective Tax

Q3 Adjusted EPS and Adjusted EBITDA Highlights

• Strong results of Pharma and Food + Beverage segments drove higher EBITDA and offset weaker results of Beauty + Home

• Continued under-absorption of overhead due to COVID-19, mainly in our beauty facilities

$0.97 $1.00

$- $0.20 $0.40 $0.60 $0.80 $1.00 $1.20

Q3 2019 Q3 2020

Adjusted Q3 EPS*

+3%$146 $157

$50,000

$100,000

$150,000

$200,000

Q3 2019 Q3 2020

Adjusted Q3 EBITDA(in millions $)

Nine Months Year-to-Date 2020 Reported Results

YTD Highlights• Pharma segment continues to perform

well through the first nine months of the year with growth over a very strong period a year ago

• Beauty + Home and Food + Beverage segments experienced a more difficult first nine months due to the impacts of COVID-19

• Progressive signs of improvement for Beauty + Home and positive results for Food + Beverage as we moved further into the year

• Pleased with the performance of our recent acquisitions, in particular FusionPKG and Noble

-2%Core Sales

Growth*

-1%Currency Effects

+3%Acquisitions

29%YTD 2019

Reported Effective Tax

29%YTD 2020

ReportedEffective Tax

$2,188 $2,180

$1,000

$1,500

$2,000

$2,500

YTD 2019 YTD 2020

Reported YTD Sales(in millions $)

Adjustments: • 2019: Restructuring initiatives of $17.3 mil;

transaction costs related to acquisitions of $1.8 mil

• 2020: Restructuring initiatives of $15.6 mil; Transaction costs related to acquisitions of $4.8 mil; Purchase accounting adjustments of $1.3 mil

Nine Months Year-to-Date 2020 Adjusted EPS and Adjusted EBITDA

29%YTD 2019Effective Tax

28%YTD 2020Effective Tax

YTD Adjusted EPS and Adjusted EBITDA Highlights• Strong Pharma results able to

compensate for COVID-related shortfalls, especially within our beauty and beverage applications

• Realizing temporary operating inefficiencies in order to maintain critical supply of product during COVID

• Recent acquisitions (CSP Technologies, FusionPKGand Noble) performing well

$461 $437

$100,000

$200,000

$300,000

$400,000

$500,000

YTD 2019 YTD 2020

Adjusted YTD EBITDA(in millions $)

-5%$3.15 $2.72

YTD 2019 YTD 2020

Adjusted YTD EPS*

Outlook

27-29%Q4 expected tax rate range(prior year Q4

Adj. EPS effective tax rate

= 28%)

Outlook Highlights

• We expect to achieve core sales growth in the fourth quarter

• Rising demand in many end markets, expected to offset COVID-19 related declines in other markets

• Expect our Pharma business to continue to do well with traditional business and pandemic-related business

• Capital expenditures estimated range for 2020 is $240 - $250 million

• Depreciation & amortization estimate for 2020 is ~$220M - $225 million

Guidance Fx Euro Rate = 1.17

$0.73$0.84 $0.84 – $0.92

Q4 2019Reported

Q4 2019Adjusted*

Q4 2020Outlook

Earnings Per Share

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures. 39

Consolidated Financial Targets

Metric3 Year

Average 2019 Q3 YTD 2020 Long-term TargetCore sales growth1 5% 3% -2% 4-7%

Adj. EBITDA2 /Sales % 20% 21% 20% 20-22%

ROIC3 13% 11% 10% 13-15%

Dividend Payout Ratio 36% 36% 40% 30-40%

Leverage Ratio ≈ 1.7X ≈ 1.7X ≈ 1.8X 1-3X1 – Excludes acquisitions and currency effects.

2 – Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.

3 – Return on invested capital = adjusted earnings before net interest and taxes, less tax effect / average capital (average of beginning of year and end of year capital) [capital = equity plus debt less cash].

4 – Cash dividends paid / adjusted earnings per share.

Strategic Priorities

Macro Trends

• Aging Population• Connectivity

• E-Commerce Supply Chain • Health and Wellness

• Sustainability• Urbanization

• Rise of Eastern Economies• Shareholder Engagement

2017Financial (five year avg)Sales Growth 3%EBITDA Margin 19%

AcquisitionsStrategic technologies in the US and EU

TalentEvolving need for greater capabilities and diversity

Geographic FocusAmericas & EU

Strategic Priorities2022Financial Sales Growth 4-7%EBITDA Margin 20-22%

Acquisitions/PartnersGlobal acquisitions, partnerships, incubators, new business models

TalentGreater diversity, inclusion and global capabilities

Geographic FocusAdded emphasis on Asia/Middle East/Eastern EU

3% (2019), -2% (2020 YTD)

Board, EVP General Counsel, CHRO, Asian Leadership, Strategy/ M&A, Innovation, Digital , Diversity Targets

External Benchmarks, Innovation Pipeline, Performance Mgmt, 6σ, Sustainability

Higher Growth, Beauty + Home and Aptar Margin Expansion

CSP Technologies, FusionPKG, BTY, Sonmol, Nanopharm, Reboul, Gateway, Noble, PureCycle, Loop, Nippon Closures

O r g a n i c G r o w t h

T a l e n t & L e a d e r s h i p

E x c e l l e n c e P i l l a r s

T r a n s f o r m a t i o n

A c q u i s i t i o n s & P a r t n e r s h i p s

Compounding Growth Story 2009 - 2019

+4.5%CAGR

Core Sales

+8%CAGR

Adjusted EPS

+9%CAGR

Dividend

• average yield over 10 years = 1.6%

• 27 consecutive years of paying increased

annual dividends

Revenue Near-term Sensitivity Related to COVID-19

Our Markets % of Revenue* Key Drivers

Pharma 38% Stable across most medicines and categories; Most prescription drugs and OTC products are easily available for delivery; Potential upside should injectable treatments be developed / grow.

Home Care 4% Stable across most categories; Potential upside with increased demand for cleaners.

Food 10% Major categories such as Condiments, Dairy and Infant Nutrition are stable; Food Service (certain closures and trays) negatively impacted by confinement and restaurant closings.

Personal Care 19% Major categories such as Grooming (including Haircare, Shaving) and Sunscreens are negatively impacted by confinement; Partially offset by higher demand for sanitizers and soaps.

Beverage 5% Majority of Beverage business is related to on-the-go beverages, including functional beverages and premium bottled water, all negatively impacted from confinement.

Beauty 24% Prestige and Mass Beauty products significantly impacted by reduced travel (travel retail sales), confinement and store closings (less usage, less opportunity to purchase and e-commerce volumes not offsetting retail product sales declines).

Q1: Crisis Early Stage

Q2: Crisis Low Point H2: Gradual Recovery

Least Affected

Most Affected

* Based on 2019 annual sales

Free Cash Flow and Capital Allocation

Highlights• Balance sheet remains strong and we have

generated more cash flow in the first nine months of 2020 than in the prior year, primarily due to improvements in working capital

• We have a consistent balanced capital allocation strategy

• Temporarily paused our share repurchasing program as a precautionary measure given near-term uncertainties

• Capital expenditures estimated range for 2020 is $220 - $240 million

• Depreciation & amortization estimate for 2020 is $220 - $230 million

$194 $208

YTD 2019 YTD 2020

YTD Free Cash Flow(in millions $)

New in 2020

“Most Responsible Companies in France”

#48up from

Merck (17), P&G (23), Apple (44), BD (46), Ball (65)

_____________________________________

Dupont (121), Estee Lauder (136), Dow (230), Eastmen (232), Alcoa(256), Westrock (257), Walmart

(263), Sonoco (293), PepsiCo (318)

270 A Listed out of 5,600+ scored

Danone, HP, L’Oreal, Apple, AZ, Bayer, Braskem, Coca-Cola,

Colgate-Palmolive, Estee Lauder, General Mills, GSK, J&J, Mars McCormick, Owens, PepsiCo, TetraPak, Unilever, Walmart

1 of 4 industry leaders on Prime Index

Ball (B-)BBillerudKorsnäs AB (B-)

SIG Combibloc Group AG (C+)

#83up from

Climate:

A up from B-

Water:

B up from C-

C+up from

??from 68

Platinum = top 1% of respondents

Other companies TBD

Ball (16), Colgate-Palmolive (26), Coca-Cola (44)

_____________________________________

Starbucks (49), West Pharma (54), McCormick (55), Sonoco (64),

P&G (72)

Recent Accolades

Stock Closure Portfolio (PCR)

Designed to Recycle Mono Material

Post Consumer Recycled (Food grade)Circular Economy

Sustainable Solutions and Ventures

Exploring connected refillable solutions

Diversity and Inclusion

• ATR included in the SPDR® SSGA Gender Diversity Index ETF (SHE)

• Board of Directors comprised of 40% Women Directors

• Director Maritza Montiel named One of the 15 Most Influential Hispanic Leaders by Latino Leaders

• sHero Award for Best Place to Work for Female Executives in China

• Partnering with Catalyst organization

• Workplace Survey focused on career advancement, job satisfaction, diversity and leadership

Matt DellaMariaSVP, Investor Relations & Communications

Phone: 815-479-5530Email: Matt.Dellamaria@aptar.com

Investor Relations Presentation...2021/01/21 · packaging, with conception -to-launch and turnkey...

Documents

Turnkey Biodiesel Plants

PRENATAL DEVELOPMENT (Conception – Birth). CONCEPTION

Sykes & Son Ltd Background - RedSky IT · Client Profile Main Contractor Sykes & Son Ltd A full turnkey solution covers all critical aspects of project delivery from conception through

Enhancing Creativity with Groupware Toolkits · Imagine: A Proxemic Ecology people, surfaces, objects, devices, fixed features Sketch conception: Nicolai Marquardt

Turnkey biodiesel refineries

Spanish Teachers Conception of Creativity

TURNKEY CONSTRUCTION

TURNKEY INTERCONNECT ASSEMBLIES

EPC Turnkey Projects

Ingeinnova turnkey projects

Turnkey Cement Gridings

SIAE MICROELETTRONICA S.p.A. Via Michelangelo …¤tter/... · n key solution turnkey solution turnkey solution turnkey solution turnkey solution siae microelettronica s.p.a. via

Blackdown turnkey insert

Turnkey solutionstechnomaps.veoliawatertechnologies.com/.../3806-AQA-TURNKEY-E… · Turnkey - solutions for land-based Aquaculture. FREDERIC GAUMET Sales Manager Aquaculture, GLOBAL

Turnkey Projects Brochure

Turnkey Solution Profile

TURNKEY SERVICES

TURNKEY FAMILY

Turnkey Solution

Turnkey Solutions - Nordimpianti€¦ · TURNKEY SER VICE GL OB AL TURNKEY Turnkey Solutions Tailored production systems for the manufacture of a wide range of prestressed concrete